Quick Answer
Pasithea Therapeutics Corp. reported Common Stock Shares Outstanding of 23.09 million shares for the year ending 2025.
- Pasithea Therapeutics Corp. showed an increase of +1,556.1% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Pasithea Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: 13.21 million shares | Q1 2022: 23.01 million shares | Q2 2022: 26.70 million shares | Q3 2022: 26.55 million shares | Q1 2023: 26.13 million shares | Q2 2023: 26.14 million shares | Q3 2023: 20.84 million shares | Q1 2024: 1.04 million shares | Q2 2024: 1.04 million shares | Q3 2024: 1.04 million shares | Q1 2025: 2.71 million shares | Q2 2025: 7.44 million shares | Q3 2025: 7.44 million shares.
- Over the full 6 years of available data (2020 to 2025), Pasithea Therapeutics Corp.'s Common Stock Shares Outstanding has grown by 209.2%.
- Historical annual values: Fiscal year 2025: 23.09 million shares | Fiscal year 2024: 1.39 million shares | Fiscal year 2023: 1.04 million shares | Fiscal year 2022: 1.30 million shares | Fiscal year 2021: 23.01 million shares | Fiscal year 2020: 7.47 million shares.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: